19-6709754-C-T
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PM5PP2PP5_Very_Strong
The NM_000064.4(C3):c.1775G>A(p.Arg592Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,461,810 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R592W) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000064.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
C3 | NM_000064.4 | c.1775G>A | p.Arg592Gln | missense_variant | 14/41 | ENST00000245907.11 | NP_000055.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
C3 | ENST00000245907.11 | c.1775G>A | p.Arg592Gln | missense_variant | 14/41 | 1 | NM_000064.4 | ENSP00000245907 | P1 |
Frequencies
GnomAD3 genomes Cov.: 29
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461810Hom.: 0 Cov.: 38 AF XY: 0.00000138 AC XY: 1AN XY: 727212
GnomAD4 genome Cov.: 29
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jan 31, 2022 | PM1, PM2, PM5, PS3, PS4 - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 01, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 592 of the C3 protein (p.Arg592Gln). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with autosomal dominant C3-related conditions (PMID: 18796626, 19590060, 29566171, 30046676). It has also been observed to segregate with disease in related individuals. This variant is also known as R570Q. ClinVar contains an entry for this variant (Variation ID: 17060). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects C3 function (PMID: 18796626). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 10, 2020 | Published functional studies demonstrate a damaging effect on binding affinity and decreased co-factor activity (Fremeaux-Bacchi et al., 2008; Schramm et al., 2015); Not observed in large population cohorts (Lek et al., 2016); Identified in one patient in a Chinese cohort with C3 glomerulopathy (Zhao et al., 2018); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29566171, 19590060, 18796626, 21902819, 19775316, 24161037, 29450785, 25486517, 27013439, 23314101, 30046676, 25608561, 32950058, 21102542) - |
Age related macular degeneration 9;C2752037:Atypical hemolytic-uremic syndrome with C3 anomaly;C3151071:Complement component 3 deficiency Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 26, 2021 | - - |
C3-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 31, 2024 | The C3 c.1775G>A variant is predicted to result in the amino acid substitution p.Arg592Gln. This variant in heterozygous state was associated with atypical haemolytic uraemic syndrome (Reported as R570Q in Fremeaux-Bacchi et al 2008. PubMed ID: 18796626; Schramm et al 2015. PubMed ID: 25608561). Of note, another missense variant (p.Arg592Trp), affecting the same amino acid, was also associated with atypical haemolytic uraemic syndrome (reported as R570W in Fremeaux-Bacchi et al 2008. PubMed ID: 18796626). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as likely pathogenic. - |
Familial Atypical Hemolytic-Uremic Syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 10, 2022 | Variant summary: C3 c.1775G>A (p.Arg592Gln) results in a conservative amino acid change located in the Alpha-2-macroglobulin, bait region domain (IPR011625) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant was absent in 251464 control chromosomes. c.1775G>A has been reported in the literature in individuals affected with Genetic Atypical Hemolytic Uremic Syndrome (example, Fremeaux-Bacchi_2008, Fidalgo_2017, Zhao_2018, Bahougne_2020). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 22% of WT activity in binding to complement regulators such as membrane coding factor (MCP), resulting in a resistance to cleavage by factor I and a decreased cofactor activity (example, Fremeaux-Bachhi_2008 and reproduced by Schramm_2015). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Atypical hemolytic-uremic syndrome with C3 anomaly Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Dec 15, 2008 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at